Ana Reyes Liebana

Dr. Ana Reyes Liebana


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
Lucía Redondo CuevasLucía Redondo Cuevas
Lucía Redondo Cuevas
LBLucia Belloch
Lucia Belloch
VMVanesa Martín-Carbonell
Vanesa Martín-Carbonell
ANAngela Nicolás
Angela Nicolás
IAIulia Alexandra
Iulia Alexandra
XCXavier Cortés
Xavier Cortés
Small intestinal bacterial overgrowth (SIBO) arises from dysbiosis in the small intestine, manifesting with abdominal symptoms. This study aims to assess the efficacy of combined antibiotic therapy, herbal supplements, probiotics, and dietary modifications in SIBO management. A total of 179 SIBO-diagnosed patients underwent clinical evaluation and breath testing. Patients were categorized into hydrogen (H2-SIBO) and methane (CH4-SIBO) groups. The control group received standard antibiotic therapy and a low-FODMAP diet, while the intervention group received additional herbal antibiotics, probiotics, and prebiotics. After treatment, both groups exhibited reduced gas levels, particularly in CH4-SIBO. Clinical remission rates were higher in the intervention group, especially in CH4-SIBO cases. Logistic regression analysis showed gas concentrations at diagnosis as significant predictors of treatment success. In conclusion, adjunctive herbal supplements and probiotics did not significantly impact gas levels, but showed potential for clinical improvement, especially in CH4-SIBO.

3 April 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
ALAna Reyes Liebana
Ana Reyes Liebana
Lucía Redondo CuevasLucía Redondo Cuevas
Lucía Redondo Cuevas
ÁNÁngela Nicolás
Ángela Nicolás
VMVanessa Martín-Carbonell
Vanessa Martín-Carbonell
LSLAURA SANCHIS
LAURA SANCHIS
XCXavier Cortés
Xavier Cortés
Background: Small intestinal bacterial overgrowth (SIBO) is a dysbiosis marked by an excessive proliferation of bacteria in the small intestine, resulting in abdominal symptoms that significantly affect patients’ quality of life. Objectives: This study aims to evaluate the impact of a comprehensive therapeutic approach in improving the quality of life of patients with SIBO. Methods: For this purpose, standardized questionnaires were used at baseline, 30 days and 90 days, including the IBS-QOL (Irritable Bowel Syndrome Quality of Life Questionnaire), the GSRS (Gastrointestinal Symptom Rating Scale), the EuroQOL-5D, and the Bristol Scale. Results: The results show that a comprehensive approach, combining pharmacological treatment, appropriate dietary intervention, and strategies aimed at improving gut microbiota and intestinal permeability, produces a sustained improvement in the quality of life of a significant proportion of patients who participated in the study. Furthermore, the results suggest that, although gas normalization is a relevant indicator, clinical improvement and quality of life depend considerably on patients’ subjective perception of their health. Conclusions: This finding underscores the importance of recognizing SIBO as a prevalent condition that requires accurate diagnoses and individualized treatments to improve patients’ well-being.